High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection

BACKGROUND & AIMS: ABT‐530 is a next‐generation hepatitis C virus (HCV) NS5A inhibitor with potent pangenotypic antiviral activity in vitro. Paritaprevir is an NS3/4A protease inhibitor codosed with ritonavir that displays in vitro activity against HCV genotypes 1–4 and 6. METHODS: Efficacy, pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Poordad, Fred, Landis, Charles S., Asatryan, Armen, Jackson, Daniel F., Ng, Teresa I., Fu, Bo, Lin, Chih‐Wei, Yao, Betty, Kort, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067610/
https://www.ncbi.nlm.nih.gov/pubmed/26778412
http://dx.doi.org/10.1111/liv.13067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067610/
https://www.ncbi.nlm.nih.gov/pubmed/26778412
http://dx.doi.org/10.1111/liv.13067

Ejemplares similares